Alpha Teknova (TKNO) Competitors $4.69 -0.11 (-2.29%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$4.70 +0.00 (+0.11%) As of 08/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TKNO vs. CRON, TRVI, ELVN, ZYME, UPB, MLYS, IMNM, ATAI, URGN, and OCSShould you be buying Alpha Teknova stock or one of its competitors? The main competitors of Alpha Teknova include Cronos Group (CRON), Trevi Therapeutics (TRVI), Enliven Therapeutics (ELVN), Zymeworks (ZYME), Upstream Bio (UPB), Mineralys Therapeutics (MLYS), Immunome (IMNM), atai Life Sciences (ATAI), Urogen Pharma (URGN), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry. Alpha Teknova vs. Its Competitors Cronos Group Trevi Therapeutics Enliven Therapeutics Zymeworks Upstream Bio Mineralys Therapeutics Immunome atai Life Sciences Urogen Pharma Oculis Alpha Teknova (NASDAQ:TKNO) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation. Do insiders & institutionals believe in TKNO or CRON? 13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 12.5% of Alpha Teknova shares are held by company insiders. Comparatively, 7.3% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings & valuation, TKNO or CRON? Cronos Group has higher revenue and earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlpha Teknova$37.74M6.65-$26.75M-$0.42-11.17Cronos Group$117.61M7.72$41.08M$0.0547.40 Do analysts recommend TKNO or CRON? Alpha Teknova presently has a consensus price target of $10.00, indicating a potential upside of 113.22%. Given Alpha Teknova's stronger consensus rating and higher probable upside, equities analysts clearly believe Alpha Teknova is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Teknova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer TKNO or CRON? In the previous week, Cronos Group had 12 more articles in the media than Alpha Teknova. MarketBeat recorded 15 mentions for Cronos Group and 3 mentions for Alpha Teknova. Cronos Group's average media sentiment score of 0.86 beat Alpha Teknova's score of 0.46 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Teknova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cronos Group 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, TKNO or CRON? Alpha Teknova has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Is TKNO or CRON more profitable? Cronos Group has a net margin of 14.19% compared to Alpha Teknova's net margin of -55.24%. Cronos Group's return on equity of -3.78% beat Alpha Teknova's return on equity.Company Net Margins Return on Equity Return on Assets Alpha Teknova-55.24% -26.51% -18.40% Cronos Group 14.19%-3.78%-3.62% SummaryCronos Group beats Alpha Teknova on 11 of the 17 factors compared between the two stocks. Get Alpha Teknova News Delivered to You Automatically Sign up to receive the latest news and ratings for TKNO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TKNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TKNO vs. The Competition Export to ExcelMetricAlpha TeknovaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$256.87M$3.09B$5.66B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-11.1720.3830.5825.12Price / Sales6.65356.76462.42114.82Price / CashN/A42.3037.4059.05Price / Book3.308.659.096.18Net Income-$26.75M-$54.65M$3.25B$264.89M7 Day Performance10.87%6.58%7.32%4.18%1 Month Performance8.82%7.54%5.41%1.99%1 Year Performance-5.25%13.73%30.66%24.22% Alpha Teknova Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TKNOAlpha Teknova2.4071 of 5 stars$4.69-2.3%$10.00+113.2%+16.7%$256.87M$37.74M-11.17240Gap DownCRONCronos Group1.089 of 5 stars$2.67+16.1%N/A-1.7%$882.76M$117.61M53.40450High Trading VolumeTRVITrevi Therapeutics3.0669 of 5 stars$7.32-1.3%$20.38+178.3%+173.5%$870.31MN/A-17.4320Analyst RevisionELVNEnliven Therapeutics2.7074 of 5 stars$18.11+2.4%$41.20+127.5%-14.9%$868.03MN/A-9.4350News CoverageEarnings ReportZYMEZymeworks2.4824 of 5 stars$12.44+3.5%$21.43+72.3%+36.8%$866.86M$122.87M-8.29460UPBUpstream Bio1.8826 of 5 stars$16.59+3.7%$56.50+240.6%N/A$862.55M$2.37M0.0038High Trading VolumeMLYSMineralys Therapeutics3.2181 of 5 stars$13.19+1.5%$32.25+144.5%+48.8%$847.28MN/A-3.5428News CoverageEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionIMNMImmunome1.8243 of 5 stars$9.66-0.3%$23.14+139.6%-26.3%$843.47M$9.04M-3.1440ATAIatai Life Sciences3.0278 of 5 stars$3.96-4.1%$11.25+184.1%+210.4%$827.39M$310K-4.3580News CoverageEarnings ReportGap UpURGNUrogen Pharma4.6226 of 5 stars$18.24+2.8%$31.43+72.3%+27.2%$820.96M$90.40M-5.49200Insider TradeAnalyst RevisionOCSOculis3.085 of 5 stars$17.97-1.3%$35.33+96.6%+50.4%$795.09M$780K-6.812Short Interest ↓ Related Companies and Tools Related Companies CRON Competitors TRVI Competitors ELVN Competitors ZYME Competitors UPB Competitors MLYS Competitors IMNM Competitors ATAI Competitors URGN Competitors OCS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TKNO) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpha Teknova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alpha Teknova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.